Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | TK1 | P04183 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584344 | 1.00 | DNMT1 (0.55) | DNMT1ADRB1TK1LMNASMN1; SMN2 | |
| SCHEMBL5983784 | 0.91 | DNMT1 (0.55) | DNMT1ADRB1TK1LMNASMN1; SMN2 | |
| SCHEMBL5983780 | 0.91 | DNMT1 (0.55) | DNMT1ADRB1TK1LMNASMN1; SMN2 | |
| SCHEMBL5983884 | 0.89 | DNMT1 (0.53) | DNMT1ADRB1TK1TK2 | |
| SCHEMBL5983881 | 0.89 | DNMT1 (0.53) | DNMT1ADRB1TK1TK2 | |
| SCHEMBL2582482 | 0.87 | DNMT1 (0.54) | DNMT1ADRB1TK1TK2 | |
| SCHEMBL9082438 | 0.87 | ADRB1 (0.41) | DNMT1ADRB1TK1LMNATK2 | |
| SCHEMBL2588008 | 0.86 | LMNA (0.58) | DNMT1ADRB1TK1LMNASMN1; SMN2 | |
| SCHEMBL2584723 | 0.86 | DNMT1 (0.55) | DNMT1ADRB1TK1LMNASMN1; SMN2 | |
| SCHEMBL4276793 | 0.86 | LMNA (0.58) | DNMT1ADRB1TK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | DNMT1 192/4885ADRB1 1775/4885TK1 102/4885 |
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | SAMHD1, TYMP, NUDT1 | DNMT1 227/4885ADRB1 2624/4885TK1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.